NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 318 filers reported holding NOVOCURE LTD in Q2 2022. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,636 | -67.4% | 101,321 | -16.2% | 0.00% | -66.7% |
Q2 2023 | $5,017 | -33.8% | 120,887 | -4.1% | 0.01% | -40.0% |
Q1 2023 | $7,578 | -51.6% | 126,014 | -41.0% | 0.01% | -52.4% |
Q4 2022 | $15,666 | -99.9% | 213,585 | +1.4% | 0.02% | -8.7% |
Q3 2022 | $16,000,000 | +7.2% | 210,585 | -1.9% | 0.02% | +21.1% |
Q2 2022 | $14,925,000 | -17.3% | 214,750 | -1.5% | 0.02% | 0.0% |
Q1 2022 | $18,058,000 | +10.1% | 217,965 | -0.2% | 0.02% | +18.8% |
Q4 2021 | $16,395,000 | -35.4% | 218,365 | 0.0% | 0.02% | -40.7% |
Q3 2021 | $25,367,000 | -47.6% | 218,365 | 0.0% | 0.03% | -46.0% |
Q2 2021 | $48,438,000 | +63.0% | 218,365 | -2.9% | 0.05% | +51.5% |
Q1 2021 | $29,718,000 | -29.4% | 224,830 | -7.6% | 0.03% | -29.8% |
Q4 2020 | $42,105,000 | +47.9% | 243,324 | -4.9% | 0.05% | +34.3% |
Q3 2020 | $28,465,000 | +83.8% | 255,729 | -2.1% | 0.04% | +75.0% |
Q2 2020 | $15,491,000 | +21.3% | 261,229 | +37.8% | 0.02% | +5.3% |
Q1 2020 | $12,770,000 | -7.7% | 189,629 | +15.5% | 0.02% | +18.8% |
Q4 2019 | $13,835,000 | +38.0% | 164,174 | +22.5% | 0.02% | +23.1% |
Q3 2019 | $10,025,000 | +12.1% | 134,060 | -5.2% | 0.01% | +18.2% |
Q2 2019 | $8,945,000 | +41.5% | 141,472 | +7.8% | 0.01% | +37.5% |
Q1 2019 | $6,322,000 | +74.7% | 131,247 | +21.4% | 0.01% | +60.0% |
Q4 2018 | $3,619,000 | -47.7% | 108,107 | -18.1% | 0.01% | -37.5% |
Q3 2018 | $6,916,000 | +76.2% | 131,977 | +5.2% | 0.01% | +60.0% |
Q2 2018 | $3,926,000 | +191.9% | 125,440 | +103.3% | 0.01% | +150.0% |
Q1 2018 | $1,345,000 | +7.9% | 61,700 | 0.0% | 0.00% | +100.0% |
Q4 2017 | $1,246,000 | +1.7% | 61,700 | 0.0% | 0.00% | -50.0% |
Q3 2017 | $1,225,000 | +14.8% | 61,700 | 0.0% | 0.00% | +100.0% |
Q2 2017 | $1,067,000 | +150.5% | 61,700 | +17.3% | 0.00% | 0.0% |
Q1 2017 | $426,000 | +3.1% | 52,601 | +0.0% | 0.00% | 0.0% |
Q4 2016 | $413,000 | -8.0% | 52,600 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $449,000 | +550.7% | 52,600 | +791.5% | 0.00% | – |
Q2 2016 | $69,000 | -18.8% | 5,900 | 0.0% | 0.00% | – |
Q1 2016 | $85,000 | – | 5,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |